A 26-week treatment, multi-center, randomized, double-blind, double- dummy, placebo-controlled, parallel-group study to assess the efficacy, and safety of indacaterol (150 microg o.d.) in patients with chronic obstructive pulmonary disease, using salmeterol (50 microg b.i.d.) as an active control.

Trial Profile

A 26-week treatment, multi-center, randomized, double-blind, double- dummy, placebo-controlled, parallel-group study to assess the efficacy, and safety of indacaterol (150 microg o.d.) in patients with chronic obstructive pulmonary disease, using salmeterol (50 microg b.i.d.) as an active control.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Indacaterol (Primary) ; Salmeterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 04 Jul 2012 Company added in the association field as reported by EudraCT.
    • 23 Jun 2010 New source identified and integrated (Clinical Trials Registry - India).
    • 09 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top